Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111753 | 1.00 | PPARG (0.78) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL1847035 | 1.00 | PPARG (0.78) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL2774800 | 0.95 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL4204124 | 0.92 | PPARG (0.69) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL4204121 | 0.92 | PPARG (0.69) | PPARGKDM4EALDH1A1MAPTPKM | |
| Trifluoroacetic Acid SCHEMBL6608290 | 0.92 | PPARG (0.67) | PPARGKDM4EALDH1A1MAPTPKM | |
| Trifluoroacetic Acid SCHEMBL6608295 | 0.92 | PPARG (0.67) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL12520464 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL1850984 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL1850981 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010013141-A2 | SUBSTANTIALLY PURE ROSIGLITAZONE HYDROGEN SULFATE | ACTAVIS GROUP PTC EHF (IS) | 2010-02-04 | — | — | WO | claimed |
| US-20090234128-A1 | Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof | LOPEZ ERNESTO DURAN | 2009-09-17 | — | — | US | claimed |
| EP-2029585-A2 | PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND POLYMORPHIC FORMS THEREOF | Medichem, S.A. (ES) | 2009-03-04 | — | — | EP | claimed |
| EP-1786808-B1 | METHOD FOR THE PREPARATION OF ROSIGLITAZONE | ZENTIVA AS (CZ) | 2008-07-09 | — | — | EP | claimed |
| US-7351832-B2 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-01 | — | — | US | claimed |
| WO-2008010089-A2 | PROCESS FOR PREPARATION OF INTERMEDIATES OF ROSIGLITAZONE, ROSIGLITAZONE AND POLYMORPHIC FORMS THEREOF | MEDICHEM, S.A. (US) | 2008-01-24 | — | — | WO | claimed |
| EP-1786808-A1 | METHOD FOR THE PREPARATION OF ROSIGLITAZONE | Zentiva, a.s. (CZ) | 2007-05-23 | — | — | EP | claimed |
| EP-1770092-A1 | Process for the preparation of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione | SMITHKLINE BEECHAM PLC (GB) | 2007-04-04 | — | — | EP | claimed |
| US-20070066662-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC | 2007-03-22 | — | — | US | claimed |
| WO-2006125402-A1 | A PROCESS FOR THE CRYSTALLIZATION OF ROSIGLITAZONE AND ITS DERIVATIVES FROM MIXED SOLVENTS | ZENTIVA, A.S. (CZ) | 2006-11-30 | — | — | WO | claimed |
| US-20020042519-A1 | Process for the preparation of substituted thiazolidinedione | SMITHKLINE BEECHAM P.L.C. | 2002-04-11 | — | — | US | claimed |
| EP-1028960-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | claimed |
| EP-0970063-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-12 | — | — | EP | claimed |
| EP-0615549-B1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICALLY ACTIVE THIAZOLIDINE OR OXAZOLIDINE COMPOUNDS BY A YEAST REDUCTASE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-09 | — | — | EP | claimed |
| WO-1999023095-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-14 | — | — | WO | claimed |
| WO-1998037073-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLIDINEDIONE | SMITHKLINE BEECHAM PLC (GB) | 1998-08-27 | — | — | WO | claimed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234128-A1 | Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof | CYP11B1, PPARD, SLC5A1 | PPARG 7/4885KDM4E 2871/4885ALDH1A1 480/4885 |
| US-20070066662-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | ARSA, TALDO1, NAT1 | PPARG 441/4885KDM4E 4296/4885ALDH1A1 150/4885 |
| US-20020042519-A1 | Process for the preparation of substituted thiazolidinedione | TALDO1, CYP11B1, CYP11B2 | PPARG 493/4885KDM4E 3071/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.